Disease activity as assessed by the MAGNIMS score predicts long-term clinical disease activity (CDA)-free status and disability progression in patients treated with subcutaneous interferon beta-1a

Authors
Category Primary study
JournalEuropean Journal of Neurology
Year 2018
This article has no abstract
Epistemonikos ID: 0df7d7fd0454f555c4a04ebd1d2caca781824673
First added on: Feb 09, 2025